How should I use Krazati(Adagrasib)?

The recommended dose is 600 mg orally, twice daily, for both NSCLC (as a single agent) and CRC (in combination with cetuximab). 

Dosage and Administration

The recommended dosage for Adagrasib is:

NSCLC: 600 mg twice daily as a single agent.

CRC: 600 mg twice daily when used with cetuximab.

Swallow the tablets whole with or without food. If vomiting occurs after a dose, do not take an additional dose; resume dosing at the next scheduled time. If a dose is missed by more than 4 hours, skip it and continue with the next scheduled dose.

Adagrasib(Krazati)
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have received at least one systemic therapy.
RELATED ARTICLES
Usage and Dosage of Adagrasib

Adagrasib is a targeted drug for the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation. It...

Wednesday, July 2nd, 2025, 15:59
/ 1
1 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved